Upregulating mTOR/S6 K Pathway by CASTOR1 Promotes Astrocyte Proliferation and Myelination in Gpam-/--induced mouse model of cerebral palsy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.In cerebral palsy (CP) models, inhibiting CASTOR1 activates the mTOR pathway, promoting astrocyte proliferation and myelin repair. This research offers a new therapeutic target for CP by modulating astrocytic mTOR signaling.
Area Of Science
- Neuroscience
- Biochemistry
- Genetics
Background
- Glycerophospholipid:protein acyltransferase (GPAM) is crucial for lipid synthesis and myelin formation, predominantly in astrocytes.
- GPAM deficiency causes a cerebral palsy (CP) mouse model exhibiting astrocyte dysfunction, reduced lipids, and myelin defects.
- The mammalian target of rapamycin (mTOR) pathway regulates cell proliferation and lipid synthesis, but its role in CP is unclear.
Purpose Of The Study
- To investigate the involvement of the mTOR pathway in GPAM-deficient mice with cerebral palsy (CP).
- To explore the regulatory role of Cytosolic Arginine Sensor 1 (CASTOR1) in the mTOR pathway within the context of CP.
Main Methods
- Utilized a GPAM-deficient (Gpam<sup>-/-</sup>) mouse model of cerebral palsy (CP).
- Assessed mTOR pathway activity, specifically the mTOR/S6K signaling cascade.
- Investigated the interaction between CASTOR1 and the mTOR pathway.
Main Results
- The mTOR pathway was found to be inhibited in Gpam<sup>-/-</sup> mice.
- CASTOR1 acts as a negative upstream regulator of the mTOR/S6K pathway.
- Inhibiting CASTOR1 reactivated mTOR/S6K signaling, enhancing astrocyte proliferation and myelination in the CP model.
- Restored motor function was observed in the Gpam<sup>-/-</sup> mice after CASTOR1 inhibition.
Conclusions
- Astrocytic mTOR signaling plays a significant role in the pathogenesis of CP.
- Targeting CASTOR1 to modulate astrocytic mTOR offers a potential therapeutic strategy for CP.
- This study identifies a novel therapeutic target for cerebral palsy treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...